查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2144385

神經基因組學檢測解決方案市場預測至2034年—按檢測類型、技術、應用、最終用戶和地區分類的全球分析

Neurogenomics Testing Solutions Market Forecasts to 2034 - Global Analysis By Test Type, Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球神經基因組學檢測解決方案市場預計將在 2026 年達到 18 億美元，並在預測期內以 10.4% 的複合年成長率成長，到 2034 年達到 40 億美元。

神經基因組學檢測方案是指專門用於分析神經系統完整遺傳和基因組結構的診斷平台和定序調查方法。它們利用先進的分子技術來識別與神經系統疾病和神經發育障礙相關的致病突變、拷貝數變異和表觀遺傳修飾。這些方案包括全基因測序、標靶基因panel和染色體微陣列分析，因此能夠對複雜的腦部疾病進行精準的分子診斷、藥物基因體學學分析和個人化治療性介入。

罕見神經系統疾病盛行率增加

隨著罕見神經系統疾病發生率的不斷上升，醫療機構不得不採用神經基因組學檢測方案，以提供更精準的分子診斷選擇。臨床上對導致複雜腦部疾病的基因變異的認知不斷提高，正在加速定序平台融入標準臨床流程。這一轉變得益於定序處理能力的提升，從而提高了診斷準確性並縮短了分析時間。因此，醫療機構正在投資基因組學技術，以實現更精準的診斷，同時最佳化患者的長期管理策略。

高成本和保險報銷的限制。

全面的基因測序和專業的生物資訊分析成本高昂，是這些技術廣泛應用的主要障礙。開發精準的檢測組合通常需要複雜的分子工作流程和先進的資料解讀技術，這會增加整體診斷成本。此外，由於高階神經基因組學檢測的保險覆蓋範圍有限，許多患者難以接受檢測。這些因素共同限制了市場擴張，尤其對於資源有限、預算緊張的診斷檢測實驗室而言更是如此。

藥物基因體學和標靶治療的擴展

隨著製藥業的擴張，標靶治療研發中對藥物藥物基因體學分析的需求日益成長，為神經基因組學檢測廠商帶來了巨大的發展機會。基因組平台以定序資料為主要輸入，無需依賴傳統處方方法，即可高效識別患者特異性的遺傳生物標記。隨著精準醫療投資的增加以及監管機構推薦基於基因的治療方案，先進神經基因組學解決方案的應用預計將大幅成長，從而創造盈利的商業機會。

資料隱私和倫理問題

替代調查方法和新興的即時基因診斷設備創新對神經基因組學檢測市場構成重大威脅。傳統的快速診斷檢測和新型微流體平台通常能提供更快的檢測結果報告速度，並且在常規臨床應用中可能更具成本效益。此外，面向消費者的基因檢測技術的進步使得基礎基因組資訊更容易取得。這種競爭可能會阻礙專業臨床神經基因組學解決方案的市場滲透，尤其是在成本和速度至關重要的領域。

新型冠狀病毒（COVID-19）的影響：

疫情初期，由於檢查室關閉，神經基因組學檢測的供應鏈受到衝擊，診斷調查也因此延誤。然而，隨後對精準分子診斷的需求激增，加速了先進定序平台在關鍵神經系統評估中的應用。疫情後，人們對個人化醫療和基因組數據整合的關注，加強了對神經基因組學技術的長期投資，推動了各個臨床領域的市場強勁復甦。

在預測期內，全基因測序（WGS）領域預計將佔據最大的市場佔有率。

由於全基因測序(WGS) 具有無與倫比的全面基因組覆蓋率和在各種臨床領域的廣泛應用，預計在預測期內，WGS 細分市場將佔據最大的市場佔有率。全基因測序具有卓越的診斷準確性，能夠有效辨識複雜的致病變異。這顯著減少了診斷失誤，並最大限度地減少了不必要的醫療干預。隨著精準分子診斷在醫療保健系統中變得日益重要，對專業 WGS 平台的需求持續激增，鞏固了其在市場上的主導地位。

預計在預測期內，次世代定序（NGS）領域將呈現最高的複合年成長率。

在預測期內，受高通量定序技術和生物資訊分析快速發展的推動，次世代定序（NGS）領域預計將呈現最高的成長率。這些技術能夠對多個基因標靶進行精確分析，從而產生高度專業且可靠的診斷結果，以滿足特定神經系統疾病的應用需求。先進的NGS平台顯著提高了定序速度、準確性和成本效益，從而大幅提升了該技術的經濟效益。因此，基因組研究投入的增加和有利的臨床趨勢正在加速商業性化應用。

市佔率最大的地區：

在預測期內，北美預計將佔據最大的市場佔有率，這主要得益於該地區成熟的分子診斷和基因組學研究產業，該產業大量採用神經基因組學檢測解決方案。北美受惠於大量的研發投入、健全的智慧財產權保護以及政府對精準醫療和基因組資料整合的支持。此外，美國和加拿大主要產業參與者對先進定序技術的早期應用，進一步鞏固了該地區的全球主導地位。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率，這主要得益於新興經濟體醫療保健的快速現代化以及分子診斷行業的擴張。中國、印度和日本等國家正加大對基因組基礎設施和精準醫療技術的投資，以滿足不斷成長的國內需求以及公眾對罕見神經系統疾病日益增強的認知。此外，有利的政府政策、不斷成長的醫療保健支出以及經濟高效的定序平台的普及，正在加速神經基因組學檢測解決方案在全球範圍內的應用。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶要求，我們可以提供主要國家的市場估算和預測，以及複合年成長率（註：需經可行性確認）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對領先公司進行基準分析。

目錄

第1章執行摘要

  • 市場概覽及主要亮點
  • 促進因素、挑戰與機遇
  • 競爭格局概述
  • 戰略洞察與建議

第2章：研究框架

  • 研究目標和範圍
  • 相關人員分析
  • 研究假設和限制
  • 調查方法

第3章 市場動態與趨勢分析

  • 市場定義與結構
  • 主要市場促進因素
  • 市場限制與挑戰
  • 投資成長機會和重點領域
  • 產業威脅與風險評估
  • 技術與創新展望
  • 新興市場/高成長市場
  • 監管和政策環境
  • 新冠疫情的影響及復甦前景

第4章：競爭環境與策略評估

  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭公司之間的競爭
  • 主要公司市佔率分析
  • 產品基準評效和效能比較

第5章 全球神經基因組學檢測解決方案市場：按檢測類型分類

  • 全基因測序（WGS）
  • 全EXOME定序（WES）
  • 目標基因面板
  • 藥物基因體學學檢測
  • 染色體微陣列分析（CMA）
  • 其他神經基因組學測試

第6章 全球神經基因體學檢測解決方案市場：依技術分類

  • 次世代定序（NGS）
  • 聚合酵素鏈鎖反應（PCR）
  • 桑格定序
  • 微陣列技術
  • 其他定序技術

第7章 全球神經基因組學檢測解決方案市場：按應用領域分類

  • 罕見神經系統疾病
  • 神經退化性疾病
  • 神經發育障礙
  • 精神疾病
  • 神經肌肉疾病
  • 其他用途

第8章 全球神經基因組學檢測解決方案市場：按最終用戶分類

  • 醫院和診所
  • 診斷與檢測實驗室以及參考實驗室
  • 學術研究機構
  • 直接面對消費者（DTC）的基因檢測公司
  • 製藥和生物技術公司
  • 其他最終用戶

第9章 全球神經基因組學檢測解決方案市場：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 比利時
    • 瑞典
    • 瑞士
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 馬來西亞
    • 新加坡
    • 越南
    • 其他亞太國家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
    • 秘魯
    • 其他南美國家
  • 世界其他地區（RoW）
    • 中東
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 以色列
      • 其他中東國家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲國家

第10章 戰略市場資訊

  • 工業價值網路和供應鏈評估
  • 空白區域和機會地圖
  • 產品演進與市場生命週期分析
  • 通路、經銷商和打入市場策略的評估

第11章 產業趨勢與策略舉措

  • 併購
  • 夥伴關係、聯盟和合資企業
  • 新產品發布和認證
  • 擴大生產能力和投資
  • 其他策略舉措

第12章：公司簡介

  • Illumina, Inc.
  • Thermo Fisher Scientific Inc.
  • Invitae Corporation
  • Ambry Genetics（Konica Minolta）
  • GeneDx（BioReference Laboratories）
  • Fulgent Genetics, Inc.
  • Blueprint Genetics
  • PreventionGenetics
  • Centogene NV
  • Athena Diagnostics（Labcorp）
  • Mayo Clinic Laboratories
  • ARUP Laboratories
  • Quest Diagnostics Incorporated
  • 23andMe, Inc.
  • Color Genomics
  • Natera, Inc.
  • PerkinElmer, Inc.
Product Code: SMRC39940

According to Stratistics MRC, the Global Neurogenomics Testing Solutions Market is accounted for $1.8 billion in 2026 and is expected to reach $4.0 billion by 2034 growing at a CAGR of 10.4% during the forecast period. Neurogenomics testing solutions refer to specialized diagnostic platforms and sequencing methodologies designed to analyze the complete genetic and genomic architecture of the nervous system. They function by utilizing advanced molecular techniques to identify pathogenic variants, copy number variations, and epigenetic modifications associated with neurological and neurodevelopmental disorders. These solutions encompass whole genome sequencing, targeted gene panels, and chromosomal microarray analyses that enable precise molecular diagnosis, pharmacogenomic profiling, and personalized therapeutic interventions for complex brain-related conditions.

Market Dynamics:

Driver:

Rising Prevalence of Rare Neurological Disorders

The rising prevalence of rare neurological disorders compels providers to adopt neurogenomics testing solutions offering precise molecular diagnostic alternatives. Growing clinical recognition of genetic variants driving complex brain conditions accelerates the integration of sequencing platforms into standard care pathways. This transition is supported by advancements in sequencing throughput, which enhance diagnostic yield and reduce analysis timelines. Consequently, institutions are investing in genomic technologies to achieve accurate diagnoses while optimizing long-term patient management strategies.

Restraint:

High Costs and Reimbursement Limitations

The substantial expenses associated with comprehensive genomic sequencing and specialized bioinformatics analysis represent a significant barrier to widespread adoption. Developing accurate testing panels often requires complex molecular workflows and sophisticated data interpretation techniques, which escalate overall diagnostic costs. Furthermore, limited insurance reimbursement coverage for advanced neurogenomic assays restricts their operational accessibility for many patients. These factors collectively constrain market expansion, particularly for diagnostic laboratories operating with limited financial resources and tight operational budgets.

Opportunity:

Expansion in Pharmacogenomics and Targeted Therapies

The expanding pharmaceutical sector presents substantial growth opportunities for neurogenomics testing manufacturers due to increasing demand for pharmacogenomic profiling in targeted drug development. Genomic platforms offer a highly effective pathway to identify patient-specific genetic biomarkers without relying on traditional prescribing methods, utilizing sequencing data as primary inputs. As investments in precision medicine expand and regulators favor genetically guided therapeutic pathways, the adoption of advanced neurogenomic solutions is expected to surge, creating lucrative enterprise avenues.

Threat:

Data Privacy and Ethical Concerns

The innovation of alternative diagnostic methodologies and emerging point-of-care genetic devices poses a considerable threat to the neurogenomics testing market. Traditional rapid diagnostic assays and novel microfluidic platforms often exhibit superior turnaround times and can be more cost-effective for routine clinical applications. Additionally, the advancement of direct-to-consumer genetic testing enhances the accessibility of basic genomic information. This competitive pressure may hinder the penetration of specialized clinical neurogenomic solutions, particularly where cost and speed are primary considerations.

Covid-19 Impact:

The pandemic initially disrupted neurogenomics testing supply chains and delayed diagnostic research due to laboratory closures. However, the subsequent surge in demand for precise molecular diagnostics accelerated the adoption of advanced sequencing platforms for critical neurological assessments. Post-pandemic, the heightened focus on personalized medicine and genomic data integration has reinforced long-term investments in neurogenomics technologies, driving robust market recovery across diverse clinical sectors.

The whole genome sequencing (WGS) segment is expected to be the largest during the forecast period

The whole genome sequencing (WGS) segment is expected to account for the largest market share during the forecast period, due to its unparalleled comprehensive genomic coverage and widespread applicability across diverse clinical sectors. Whole genome sequencing offers exceptional diagnostic yield and operates effectively in identifying complex pathogenic variants, which significantly reduces diagnostic odysseys and minimizes unnecessary medical interventions. As healthcare systems increasingly prioritize precise molecular diagnostic methods, the demand for specialized WGS platforms continues to surge, thereby solidifying their dominant market position.

The next-generation sequencing (NGS) segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the next-generation sequencing (NGS) segment is predicted to witness the highest growth rate, driven by rapid advancements in high-throughput sequencing technologies and bioinformatics analytics. These technologies enable the precise analysis of multiple genetic targets to produce highly specialized and robust diagnostic outputs tailored for specific neurological applications. The ability to enhance sequencing speed, accuracy, and cost-efficiency through advanced NGS platforms significantly improves process economics. Consequently, increasing investments in genomic research and favorable clinical trends are accelerating commercial adoption.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, due to the presence of well-established molecular diagnostics and genomic research industries that heavily utilize neurogenomics testing solutions. The region benefits from substantial research and development investments, robust intellectual property protection, and supportive government initiatives promoting precision medicine and genomic data integration. Furthermore, the early adoption of advanced sequencing technologies by key industry players in the United States and Canada reinforces the region's dominant position globally.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, due to rapid healthcare modernization and expanding molecular diagnostics sectors in emerging economies. Countries such as China, India, and Japan are increasingly investing in genomic infrastructure and precision medicine technologies to meet growing domestic demand and rising awareness of rare neurological disorders. Additionally, favorable government policies, rising healthcare expenditures, and the availability of cost-effective sequencing platforms are collectively driving the accelerated adoption of neurogenomics testing solutions globally.

Key players in the market

Some of the key players in Neurogenomics Testing Solutions Market include Illumina, Inc., Thermo Fisher Scientific Inc., Invitae Corporation, Ambry Genetics (Konica Minolta), GeneDx (BioReference Laboratories), Fulgent Genetics, Inc., Blueprint Genetics, PreventionGenetics, Centogene N.V., Athena Diagnostics (Labcorp), Mayo Clinic Laboratories, ARUP Laboratories, Quest Diagnostics Incorporated, 23andMe, Inc., Color Genomics, Natera, Inc., and PerkinElmer, Inc.

Key Developments:

In September 2026, Illumina, Inc. launched a next-generation whole genome sequencing platform optimized for rare neurological disorders, achieving a thirty percent improvement in diagnostic yield while significantly reducing analysis time requirements for global clinical laboratories.

In August 2026, Thermo Fisher Scientific Inc. expanded its pharmacogenomics testing capacity in Europe through a strategic partnership with a leading research hospital, enabling the scalable deployment of novel targeted gene panels for personalized drug therapies.

In July 2026, Invitae Corporation secured a major supply agreement to provide customized chromosomal microarray analysis for a prominent pediatric network, facilitating the efficient integration of advanced diagnostic tools into next-generation neurodevelopmental assessment ecosystems globally.

Test Types Covered:

  • Whole Genome Sequencing (WGS)
  • Whole Exome Sequencing (WES)
  • Targeted Gene Panels
  • Pharmacogenomics Testing
  • Chromosomal Microarray Analysis (CMA)
  • Other Neurogenomic Tests

Technologies Covered:

  • Next-Generation Sequencing (NGS)
  • Polymerase Chain Reaction (PCR)
  • Sanger Sequencing
  • Microarray Technology
  • Other Sequencing Technologies

Applications Covered:

  • Rare Neurological Disorders
  • Neurodegenerative Diseases
  • Neurodevelopmental Disorders
  • Psychiatric Disorders
  • Neuromuscular Disorders
  • Other Applications

End Users Covered:

  • Hospitals and Clinics
  • Diagnostic and Reference Laboratories
  • Academic and Research Institutes
  • Direct-to-Consumer (DTC) Genetic Testing Companies
  • Pharmaceutical and Biotechnology Companies
  • Other End Users

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Neurogenomics Testing Solutions Market, By Test Type

  • 5.1 Whole Genome Sequencing (WGS)
  • 5.2 Whole Exome Sequencing (WES)
  • 5.3 Targeted Gene Panels
  • 5.4 Pharmacogenomics Testing
  • 5.5 Chromosomal Microarray Analysis (CMA)
  • 5.6 Other Neurogenomic Tests

6 Global Neurogenomics Testing Solutions Market, By Technology

  • 6.1 Next-Generation Sequencing (NGS)
  • 6.2 Polymerase Chain Reaction (PCR)
  • 6.3 Sanger Sequencing
  • 6.4 Microarray Technology
  • 6.5 Other Sequencing Technologies

7 Global Neurogenomics Testing Solutions Market, By Application

  • 7.1 Rare Neurological Disorders
  • 7.2 Neurodegenerative Diseases
  • 7.3 Neurodevelopmental Disorders
  • 7.4 Psychiatric Disorders
  • 7.5 Neuromuscular Disorders
  • 7.6 Other Applications

8 Global Neurogenomics Testing Solutions Market, By End User

  • 8.1 Hospitals and Clinics
  • 8.2 Diagnostic and Reference Laboratories
  • 8.3 Academic and Research Institutes
  • 8.4 Direct-to-Consumer (DTC) Genetic Testing Companies
  • 8.5 Pharmaceutical and Biotechnology Companies
  • 8.6 Other End Users

9 Global Neurogenomics Testing Solutions Market, By Geography

  • 9.1 North America
    • 9.1.1 United States
    • 9.1.2 Canada
    • 9.1.3 Mexico
  • 9.2 Europe
    • 9.2.1 United Kingdom
    • 9.2.2 Germany
    • 9.2.3 France
    • 9.2.4 Italy
    • 9.2.5 Spain
    • 9.2.6 Netherlands
    • 9.2.7 Belgium
    • 9.2.8 Sweden
    • 9.2.9 Switzerland
    • 9.2.10 Poland
    • 9.2.11 Rest of Europe
  • 9.3 Asia Pacific
    • 9.3.1 China
    • 9.3.2 Japan
    • 9.3.3 India
    • 9.3.4 South Korea
    • 9.3.5 Australia
    • 9.3.6 Indonesia
    • 9.3.7 Thailand
    • 9.3.8 Malaysia
    • 9.3.9 Singapore
    • 9.3.10 Vietnam
    • 9.3.11 Rest of Asia Pacific
  • 9.4 South America
    • 9.4.1 Brazil
    • 9.4.2 Argentina
    • 9.4.3 Colombia
    • 9.4.4 Chile
    • 9.4.5 Peru
    • 9.4.6 Rest of South America
  • 9.5 Rest of the World (RoW)
    • 9.5.1 Middle East
      • 9.5.1.1 Saudi Arabia
      • 9.5.1.2 United Arab Emirates
      • 9.5.1.3 Qatar
      • 9.5.1.4 Israel
      • 9.5.1.5 Rest of Middle East
    • 9.5.2 Africa
      • 9.5.2.1 South Africa
      • 9.5.2.2 Egypt
      • 9.5.2.3 Morocco
      • 9.5.2.4 Rest of Africa

10 Strategic Market Intelligence

  • 10.1 Industry Value Network and Supply Chain Assessment
  • 10.2 White-Space and Opportunity Mapping
  • 10.3 Product Evolution and Market Life Cycle Analysis
  • 10.4 Channel, Distributor, and Go-to-Market Assessment

11 Industry Developments and Strategic Initiatives

  • 11.1 Mergers and Acquisitions
  • 11.2 Partnerships, Alliances, and Joint Ventures
  • 11.3 New Product Launches and Certifications
  • 11.4 Capacity Expansion and Investments
  • 11.5 Other Strategic Initiatives

12 Company Profiles

  • 12.1 Illumina, Inc.
  • 12.2 Thermo Fisher Scientific Inc.
  • 12.3 Invitae Corporation
  • 12.4 Ambry Genetics (Konica Minolta)
  • 12.5 GeneDx (BioReference Laboratories)
  • 12.6 Fulgent Genetics, Inc.
  • 12.7 Blueprint Genetics
  • 12.8 PreventionGenetics
  • 12.9 Centogene N.V.
  • 12.10 Athena Diagnostics (Labcorp)
  • 12.11 Mayo Clinic Laboratories
  • 12.12 ARUP Laboratories
  • 12.13 Quest Diagnostics Incorporated
  • 12.14 23andMe, Inc.
  • 12.15 Color Genomics
  • 12.16 Natera, Inc.
  • 12.17 PerkinElmer, Inc.

List of Tables

  • Table 1 Global Neurogenomics Testing Solutions Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Neurogenomics Testing Solutions Market Outlook, By Test Type (2023-2034) ($MN)
  • Table 3 Global Neurogenomics Testing Solutions Market Outlook, By Whole Genome Sequencing (WGS) (2023-2034) ($MN)
  • Table 4 Global Neurogenomics Testing Solutions Market Outlook, By Whole Exome Sequencing (WES) (2023-2034) ($MN)
  • Table 5 Global Neurogenomics Testing Solutions Market Outlook, By Targeted Gene Panels (2023-2034) ($MN)
  • Table 6 Global Neurogenomics Testing Solutions Market Outlook, By Pharmacogenomics Testing (2023-2034) ($MN)
  • Table 7 Global Neurogenomics Testing Solutions Market Outlook, By Chromosomal Microarray Analysis (CMA) (2023-2034) ($MN)
  • Table 8 Global Neurogenomics Testing Solutions Market Outlook, By Other Neurogenomic Tests (2023-2034) ($MN)
  • Table 9 Global Neurogenomics Testing Solutions Market Outlook, By Technology (2023-2034) ($MN)
  • Table 10 Global Neurogenomics Testing Solutions Market Outlook, By Next-Generation Sequencing (NGS) (2023-2034) ($MN)
  • Table 11 Global Neurogenomics Testing Solutions Market Outlook, By Polymerase Chain Reaction (PCR) (2023-2034) ($MN)
  • Table 12 Global Neurogenomics Testing Solutions Market Outlook, By Sanger Sequencing (2023-2034) ($MN)
  • Table 13 Global Neurogenomics Testing Solutions Market Outlook, By Microarray Technology (2023-2034) ($MN)
  • Table 14 Global Neurogenomics Testing Solutions Market Outlook, By Other Sequencing Technologies (2023-2034) ($MN)
  • Table 15 Global Neurogenomics Testing Solutions Market Outlook, By Application (2023-2034) ($MN)
  • Table 16 Global Neurogenomics Testing Solutions Market Outlook, By Rare Neurological Disorders (2023-2034) ($MN)
  • Table 17 Global Neurogenomics Testing Solutions Market Outlook, By Neurodegenerative Diseases (2023-2034) ($MN)
  • Table 18 Global Neurogenomics Testing Solutions Market Outlook, By Neurodevelopmental Disorders (2023-2034) ($MN)
  • Table 19 Global Neurogenomics Testing Solutions Market Outlook, By Psychiatric Disorders (2023-2034) ($MN)
  • Table 20 Global Neurogenomics Testing Solutions Market Outlook, By Neuromuscular Disorders (2023-2034) ($MN)
  • Table 21 Global Neurogenomics Testing Solutions Market Outlook, By Other Applications (2023-2034) ($MN)
  • Table 22 Global Neurogenomics Testing Solutions Market Outlook, By End User (2023-2034) ($MN)
  • Table 23 Global Neurogenomics Testing Solutions Market Outlook, By Hospitals and Clinics (2023-2034) ($MN)
  • Table 24 Global Neurogenomics Testing Solutions Market Outlook, By Diagnostic and Reference Laboratories (2023-2034) ($MN)
  • Table 25 Global Neurogenomics Testing Solutions Market Outlook, By Academic and Research Institutes (2023-2034) ($MN)
  • Table 26 Global Neurogenomics Testing Solutions Market Outlook, By Direct-to-Consumer (DTC) Genetic Testing Companies (2023-2034) ($MN)
  • Table 27 Global Neurogenomics Testing Solutions Market Outlook, By Pharmaceutical and Biotechnology Companies (2023-2034) ($MN)
  • Table 28 Global Neurogenomics Testing Solutions Market Outlook, By Other End Users (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.